Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU, Leucovorin, Gemcitabine, and Cisplatin in Urothelial and Urachal Adenocarcinoma
NCT00082706Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2003
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, gemcitabine and cisplatin in Adenocarcinoma of the urinary bladder and urachal adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate and Overall Survival up to 22 years. Started Apr 2003; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidgemcitabinecisplatin
03
Conditions
Adenocarcinoma of the urinary bladderurachal adenocarcinoma
Beyond the preview
Go deeper on NCT00082706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082706.